|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/15/13 Mimedx Group, Inc. 10-K 12/31/12 70:10M Broadridge Fin’l So… Inc |
Document/Exhibit Description Pages Size
1: 10-K Mimedx Group Inc 10-K 12-31-2012 HTML 1.04M
2: EX-10.54 Material Contract HTML 39K
3: EX-10.55 Material Contract HTML 27K
4: EX-10.56 Material Contract HTML 96K
5: EX-23.1 Consent of Experts or Counsel HTML 19K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 27K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 27K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 21K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 21K
47: R1 Document and Entity Information HTML 48K
37: R2 Consolidated Balance Sheets HTML 126K
45: R3 Consolidated Balance Sheets (Parenthetical) HTML 56K
49: R4 Consolidated Statements of Operations HTML 70K
64: R5 Consolidated Statements of Stockholders' Equity HTML 130K
39: R6 Consolidated Statements of Stockholders' Equity HTML 22K
(Parenthetical)
44: R7 Consolidated Statements of Cash Flows HTML 150K
34: R8 Consolidated Statements of Cash Flows HTML 76K
(Parenthetical)
26: R9 Nature of Business HTML 24K
66: R10 Significant Accounting Policies HTML 124K
51: R11 Liquidity and Management's Plans HTML 22K
50: R12 Acquisition of Surgical Biologics, LLC HTML 85K
55: R13 Inventories HTML 33K
56: R14 Property and Equipment HTML 36K
54: R15 Intangible Assets and Royalty Agreement HTML 96K
57: R16 Accrued Expenses HTML 30K
46: R17 Long-Term Debt HTML 54K
48: R18 Common Stock Placements HTML 36K
53: R19 Equity HTML 185K
70: R20 Income Taxes HTML 58K
60: R21 Related Party Transactions HTML 38K
41: R22 401k Plan HTML 30K
52: R23 Commitments HTML 30K
43: R24 Subsequent Events HTML 24K
20: R25 Significant Accounting Policies (Policies) HTML 222K
61: R26 Significant Accounting Policies (Tables) HTML 65K
67: R27 Acquisition of Surgical Biologics, LLC (Tables) HTML 72K
30: R28 Inventories (Tables) HTML 30K
29: R29 Property and Equipment (Tables) HTML 33K
32: R30 Intangible Assets and Royalty Agreement (Tables) HTML 96K
33: R31 Accrued Expenses (Tables) HTML 27K
35: R32 Long-Term Debt (Tables) HTML 47K
19: R33 Equity (Tables) HTML 182K
58: R34 Income Taxes (Tables) HTML 50K
40: R35 Related Party Transactions (Tables) HTML 33K
42: R36 Commitments (Tables) HTML 25K
23: R37 Nature of Business (Details) HTML 21K
69: R38 Significant Accounting Policies (Details) HTML 157K
16: R39 Liquidity and Management's Plans (Details) HTML 31K
36: R40 Acquisition of Surgical Biologics, LLC (Details) HTML 177K
63: R41 Inventories (Details) HTML 38K
22: R42 Property and Equipment (Details) HTML 34K
28: R43 Intangible Assets and Royalty Agreement (Details) HTML 122K
31: R44 Accrued Expenses (Details) HTML 31K
38: R45 Long-Term Debt (Details) HTML 116K
18: R46 Common Stock Placements (Details) HTML 70K
25: R47 Equity (Details) HTML 285K
17: R48 Income Taxes (Details) HTML 95K
62: R49 Related Party Transactions (Details) HTML 31K
21: R50 401k Plan (Details) HTML 32K
59: R51 Commitments (Details) HTML 28K
24: R52 Subsequent Events (Details) HTML 37K
68: XML IDEA XML File -- Filing Summary XML 94K
27: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 1.52M
10: EX-101.INS XBRL Instance -- mdxg-20121231 XML 2.21M
12: EX-101.CAL XBRL Calculations -- mdxg-20121231_cal XML 193K
13: EX-101.DEF XBRL Definitions -- mdxg-20121231_def XML 640K
14: EX-101.LAB XBRL Labels -- mdxg-20121231_lab XML 2.22M
15: EX-101.PRE XBRL Presentations -- mdxg-20121231_pre XML 1.17M
11: EX-101.SCH XBRL Schema -- mdxg-20121231 XSD 203K
65: ZIP XBRL Zipped Folder -- 0001140361-13-012765-xbrl Zip 225K
|
2.
|
Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;
|
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;
|
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
|
(a)
|
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared,
|
|
(b)
|
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles,
|
|
(c)
|
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation, and
|
|
(d)
|
disclosed in this annual report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):
|
|
(a)
|
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
|
(b)
|
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
|
/s/: Michael J. Senken
|
||
|
Michael J. Senken
|
||
|
Chief Financial Officer
|
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/15/13 | None on these Dates | ||
| For Period end: | 12/31/12 | |||
| List all Filings | ||||